{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rivaroxaban&page=2",
    "query": {
      "intervention": "rivaroxaban",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=rivaroxaban&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-28T19:53:11.414Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01999179",
      "title": "Post-thrombotic Syndrome & Predictors of Recurrence in Catheter-related Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Venous Thrombosis",
        "Neoplasms"
      ],
      "interventions": [
        {
          "name": "Heparin, Low-Molecular-Weight, or direct oral anticoagulants",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Medical College of Wisconsin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2014-06",
      "completion_date": "2022-04-26",
      "has_results": true,
      "last_update_posted_date": "2022-05-18",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 3,
      "location_summary": "Minneapolis, Minnesota • Columbus, Ohio • Milwaukee, Wisconsin",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Columbus",
          "state": "Ohio"
        },
        {
          "city": "Milwaukee",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01999179"
    },
    {
      "nct_id": "NCT04059679",
      "title": "Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Coronary Artery Disease",
        "Peripheral Artery Disease"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban 2.5 Mg Oral Tablet",
          "type": "DRUG"
        },
        {
          "name": "Aspirin 81 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "LifeBridge Health",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2020-01-30",
      "completion_date": "2021-08",
      "has_results": false,
      "last_update_posted_date": "2020-10-14",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04059679"
    },
    {
      "nct_id": "NCT02309411",
      "title": "EINSTEIN Junior Phase II: Oral Rivaroxaban in Young Children With Venous Thrombosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Venous Thromboembolism"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban (Xarelto, BAY59-7939)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "5 Years",
        "sex": "ALL",
        "summary": "6 Months to 5 Years"
      },
      "enrollment_count": 46,
      "start_date": "2015-01-15",
      "completion_date": "2017-04-05",
      "has_results": true,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 5,
      "location_summary": "Gainesville, Florida • Pensacola, Florida • Atlanta, Georgia + 2 more",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        },
        {
          "city": "Pensacola",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02309411"
    },
    {
      "nct_id": "NCT02833948",
      "title": "Comparison of a Rivaroxaban-based Strategy With an Antiplatelet-based Strategy Following Successful TAVR for the Prevention of Leaflet Thickening and Reduced Leaflet Motion as Evaluated by Four-dimensional, Volume-rendered Computed Tomography (4DCT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Aortic Valve Stenosis",
        "Cardiovascular Diseases",
        "Heart Valve Diseases",
        "Ventricular Outflow Obstruction",
        "Thrombosis"
      ],
      "interventions": [
        {
          "name": "Acetylsalicylic acid",
          "type": "DRUG"
        },
        {
          "name": "Clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ECRI bv",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 231,
      "start_date": "2016-05",
      "completion_date": "2019-03-06",
      "has_results": true,
      "last_update_posted_date": "2020-01-18",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • New York, New York • Philadelphia, Pennsylvania + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "New York",
          "state": "New York"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02833948"
    },
    {
      "nct_id": "NCT06055920",
      "title": "The PEERLESS II Study",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Pulmonary Embolism"
      ],
      "interventions": [
        {
          "name": "FlowTriever System",
          "type": "DEVICE"
        },
        {
          "name": "Anticoagulation Agents",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Inari Medical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1200,
      "start_date": "2023-11-17",
      "completion_date": "2026-10",
      "has_results": false,
      "last_update_posted_date": "2026-09-11",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 42,
      "location_summary": "Birmingham, Alabama • Pasadena, California • Aurora, Colorado + 35 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Pasadena",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06055920"
    },
    {
      "nct_id": "NCT03702582",
      "title": "Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke",
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2019-04-30",
      "completion_date": "2023-10-01",
      "has_results": true,
      "last_update_posted_date": "2026-05-19",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03702582"
    },
    {
      "nct_id": "NCT02900170",
      "title": "Can Rivaroxaban Lead to Anticoagulation-Related Nephropathy?",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Acute Kidney Injury"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Albert Einstein Healthcare Network",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "60 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "60 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2016-07",
      "completion_date": "2018-06-11",
      "has_results": true,
      "last_update_posted_date": "2020-07-07",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02900170"
    },
    {
      "nct_id": "NCT00809965",
      "title": "An Efficacy and Safety Study for Rivaroxaban in Patients With Acute Coronary Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Acute Coronary Syndrome",
        "Myocardial Infarction",
        "Myocardial Ischemia",
        "Unstable Angina"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "Rivaroxaban 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Standard of care",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johnson & Johnson Pharmaceutical Research & Development, L.L.C.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15526,
      "start_date": "2008-11",
      "completion_date": "2011-09",
      "has_results": true,
      "last_update_posted_date": "2014-09-17",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 73,
      "location_summary": "Birmingham, Alabama • Geneva, Alabama • Mobile, Alabama + 70 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Geneva",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Burbank",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00809965"
    },
    {
      "nct_id": "NCT01830543",
      "title": "A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Percutaneous Coronary Intervention"
      ],
      "interventions": [
        {
          "name": "rivaroxaban 2.5 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 15 mg",
          "type": "DRUG"
        },
        {
          "name": "rivaroxaban 10 mg",
          "type": "DRUG"
        },
        {
          "name": "aspirin (ASA)",
          "type": "DRUG"
        },
        {
          "name": "vitamin K antagonist (VKA)",
          "type": "DRUG"
        },
        {
          "name": "clopidogrel",
          "type": "DRUG"
        },
        {
          "name": "prasugrel",
          "type": "DRUG"
        },
        {
          "name": "ticagrelor",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Janssen Scientific Affairs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2124,
      "start_date": "2013-05-10",
      "completion_date": "2016-07-28",
      "has_results": true,
      "last_update_posted_date": "2017-09-19",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 86,
      "location_summary": "Huntsville, Alabama • Los Alamitos, California • Mission Viejo, California + 83 more",
      "locations": [
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Mission Viejo",
          "state": "California"
        },
        {
          "city": "Oceanside",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01830543"
    },
    {
      "nct_id": "NCT01747746",
      "title": "Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Atrial Fibrillation",
        "Stroke",
        "Thrombo-embolism",
        "Bleeding"
      ],
      "interventions": [
        {
          "name": "Rivaroxaban",
          "type": "DRUG"
        },
        {
          "name": "Warfarin and Enoxaparin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Cook County Health",
      "sponsor_class": "OTHER_GOV",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2012-10",
      "completion_date": "2014-10",
      "has_results": false,
      "last_update_posted_date": "2015-02-03",
      "last_synced_at": "2026-09-28T19:53:11.414Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01747746"
    }
  ]
}